Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service (Process Development), By Drug Type (Biologics, Biosimilars), By Type, By Scale of Operation, By Therapeutic Area, By Region, And Segment Forecasts
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service (Process Development), By Drug Type (Biologics, Biosimilars), By Type, By Scale of Operation, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.
The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development
Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process
Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development
The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition
Please note The report will be delivered in 2-3 business days upon order notification.
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.2.1. Information Procurement
1.3. Information or Data Analysis
1.4. Methodology
1.5. Research Scope and Assumptions
1.6. Market Formulation & Validation
1.7. Country Based Segment Share Calculation
1.8. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pay TV Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.2. Market Restraints Analysis
3.2.3. Industry Challenges
3.3. Pay TV Market Analysis Tools
3.3.1. Porter’s Analysis
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological Landscape
3.3.2.4. Environmental Landscape
3.3.2.5. Legal Landscape
Chapter 4. Pay TV Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Pay TV Market: Technology Movement Analysis, USD Billion, 2024 & 2030
4.3. Cable TV
4.3.1. Cable TV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. Satellite TV
4.4.1. Satellite TV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)